切换至 "中华医学电子期刊资源库"

中华肾病研究电子杂志 ›› 2015, Vol. 04 ›› Issue (03) : 118 -122. doi: 10.3877/cma.j.issn.2095-3216.2015.03.002

所属专题: 文献

述评

继发性甲状旁腺功能亢进的治疗策略
张凌1()   
  1. 1. 100029 北京,中日友好医院肾内科
  • 出版日期:2015-06-28
  • 通信作者: 张凌
  • 基金资助:
    北京市科委首都临床特色应用研究与成果推广资助项目(Z15110700400000)

Strategy for the treatment of secondary hyperparathyroidism

Ling Zhang1,()   

  1. 1. Department of Nephrology, China-Japan Friendship Hospital, Beijing 100029, China
  • Published:2015-06-28
  • Corresponding author: Ling Zhang
  • About author:
    Corresponding author: Zhang Ling, Email:
引用本文:

张凌. 继发性甲状旁腺功能亢进的治疗策略[J]. 中华肾病研究电子杂志, 2015, 04(03): 118-122.

Ling Zhang. Strategy for the treatment of secondary hyperparathyroidism[J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2015, 04(03): 118-122.

继发性甲状旁腺功能亢进(SHPT)已成为慢性肾脏病(CKD)常见的并发症之一,严重影响患者生活质量。其治疗策略包括药物、手术和介入。药物包括非选择性和选择性活性维生素D、拟钙剂(西那卡塞),药物治疗期间强调动态观察血清全段甲状旁腺激素(iPTH)和血清钙、磷的变化,以及时调整药物剂量。药物治疗无效且具备手术指征者,可考虑甲状旁腺切除手术(PTX)或超声介入治疗。PTX前需要高频彩超和(或)99Tcm-MIBI双时相显像用于甲状旁腺的定位诊断。PTX有三种术式,其中甲状旁腺全切除加移植是目前最常用的术式。对于不能耐受手术和需要再次PTX的患者可以选择一种新的治疗策略,即彩色超声介导下甲状旁腺热消融术。

Secondary hyperparathyroidism (SHPT) has become one of the most common complications of chronic kidney disease (CKD), and seriously affects the patients′ quality of life, whose treatment strategy consists of medication, surgery, and intervention. Its medications include non-selective and selective active vitamin D and cinacalcet, during which the changes of serum intact parathyroid hormone (iPTH), calcium, and phosphorus are monitored, so that the doses of drugs can be timely adjusted. When medical treatment is ineffective and the patient has the indication for surgery, parathyroidectomy (PTX) or ultrasound interventional therapy can be considered. High frequency color ultrasound and/or 99Tcm-MIBI dual-phase scintigraphy are/is required for the preoperative localization diagnosis of parathyroid. There are three parathyroidectomy methods, among which total parathyroidectomy plus autotransplantation is currently the most-used surgical method. Color ultrasound-guided thermal ablation of parathyroid gland may be used as a new treatment strategy for patients who can′t tolerate PTX or requires a second PTX.

[1]
Young EW, Albert JM, Satayathum S, et al. Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study [J]. Kidney Int,2005,67(3): 1179-1187.
[2]
Kidney Disease:Improving Global Outcomes (KDIGO) CKD-MBD Work Group.KDIGO clinical practice guideline for the diagnosis, evaluation, prevention and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD)[J]. Kidney Int, 2009,76(1):S1-S130.
[3]
Fukagawa M, Yokoyama K, Koiwa F, et al. Clinical practice guideline for the management of chronic kidney disease-mineral and bone disorder[J]. Ther Apher Dial, 2013, 17(3): 247-288.
[4]
K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease[J]. Am J Kidney Dis, 2003, 42(4 Suppl 3): S1-S201.
[5]
Yan Y, Qian J, Chen N, et al. Efficacy and initial dose determination of paricalcitol for treatment of secondary hyperparathyroidism in Chinese subjects [J]. Clin Nephrol, 2014, 81(1): 20-29.
[6]
Teng M, Wolf M, Lowrie E, et al. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy [J]. N Engl J Med, 2003, 349(5): 446-456.
[7]
Fukagawa M, Yumita S, Akizawa T, et al. Cinacalcet (KRN1493) effectively decreases the serum intact PTH level with favorable control of the serum phosphorous and calcium level in Japanese patients [J].Nephrol Dial Transplant,2008, 23(1):328-335.
[8]
Block GA, Martin KJ, Francisco AL,et al.Cinacalcet for secondary hyperparathyroidism patients receiving hemodialysis [J].N Eng1 J Med,2004,350(15):1516-1525.
[9]
Zitt E, Rix M, Fouque D, et al. Effectiveness of cinacalcet in patients with recurrent/persistent secondary hyperparathyroidism following parathyroidectomy: results of the ECHO study [J]. Nephrol Dial Transplant, 2011, 26(6):1956-1961.
[10]
Ghani A, Baxter P.Surgical parathyroidectomy versus cinacalcet therapy:In the management of secondary hyperparathyroidism [J].Otolaryngol Head Neck Surg, 2012, 146(2): 220-225.
[11]
Schneider R, Kolios G, Koch BM,et al. An economic comparison of surgical and medical therapy in patient with secondary hyperparathyroidism-the German perspective [J].Surgery, 2010, 148(6): 1091-1099.
[12]
姚力,张凌等.甲状旁腺切除术治疗难治性甲状旁腺功能亢进症89例疗效评价[J].中国血液净化,2009,8(8):431-436.
[13]
花瞻,姚力,张凌,等.肾性甲状旁腺功能亢进外科治疗术前高频彩超和99Tcm-MIBI双时相显像的应用[J]. 中国骨质疏松杂志,2010,16(8): 580-583.
[14]
Shih ML, Duh QY, Hsieh CB, et al. Total parathyroidectomy without autotransplantation for secondary hyperparathyroidism [J]. World J Surg, 2009, 33(2): 248-254.
[15]
Milas M, Weber C. Near-total parathyroidectomy is beneficial for patients with secondary and tertiary hyperparathyroidism [J]. Surgery, 2004, 136(6): 1252-1260.
[16]
Dotzenrath C, Cupisti K, Goretzki E, et al. Operative treatment of renal autonomous hyperparathyroidism: cause of persistent or recurrent disease in 304 patients [J]. Langenbecks Arch Surg, 2003, 387(9-10): 348-354.
[17]
张凌,刘亚绵,卞维静,等. 超声引导下甲状旁腺无水酒精注射治疗继发性甲状旁腺功能亢进[J].中华内科杂志,2001, 16 (12): 914-916.
[18]
章建全,仇明,盛建国,等. 超声引导下经皮穿刺热消融治疗甲状旁腺结节[J]. 第二军医大学学报,2013,34(4):362-370.
[19]
中华医学会肾脏病学分会工作组.慢性肾脏病矿物质与骨异常诊治指导[J].中华肾脏病杂志,2014,2(30):S1-S69.
[1] 徐博, 刘金成, 李静, 刘丽文, 周梦垚, 左蕾, 邵红, 胡芮, 朱晓丽, 刘兵. Liwen术式治疗肥厚型心肌病合并完全性右束支传导阻滞的临床研究[J]. 中华医学超声杂志(电子版), 2020, 17(05): 421-426.
[2] 张冲, 周丁华, 刘智伟, 王进, 吕伟, 程宇. 新型高频方波电脉冲对大鼠肝癌消融治疗的影响[J]. 中华损伤与修复杂志(电子版), 2020, 15(06): 454-464.
[3] 冯含昕, 赵阳, 徐锋, 鞠明光, 戴朝六. 微波消融技术在肝癌治疗的应用现状和展望[J]. 中华普通外科学文献(电子版), 2020, 14(06): 458-462.
[4] 李娜, 梁栋, 杨秦蘅. 乳腺肿瘤射频消融治疗技术要点[J]. 中华普通外科学文献(电子版), 2020, 14(05): 380-384.
[5] 周文斌, 王水. 能量消融技术在乳腺良性疾病应用现状和展望[J]. 中华普外科手术学杂志(电子版), 2023, 17(03): 237-239.
[6] 许语阳, 吕云福, 王葆春. 乙肝后肝硬化门静脉高压症脾肿大外科治疗进展[J]. 中华肝脏外科手术学电子杂志, 2023, 12(04): 469-473.
[7] 陈文娟, 贺需旗, 余萱, 李凯, 曾庆劲. 肝脏局灶性结节性增生超声引导下热消融疗效分析[J]. 中华肝脏外科手术学电子杂志, 2022, 11(02): 188-192.
[8] 晋云, 王峻峰, 胡苹苹, 杨超, 孙志为, 储心昀, 杨蕾. 腹腔镜第一肝门阻断在微波消融治疗巨大肝血管瘤中的应用[J]. 中华肝脏外科手术学电子杂志, 2022, 11(01): 71-75.
[9] 周瑞, 李珊, 万文军, 陈晓明, 王兵. 手术切除与局部热消融治疗小肝癌预后比较[J]. 中华肝脏外科手术学电子杂志, 2021, 10(03): 258-262.
[10] 王青兵, 王雁军, 张勇, 沈志玲, 肖建安. 射频消融在老年结直肠癌肝转移治疗中的疗效分析[J]. 中华肝脏外科手术学电子杂志, 2021, 10(03): 306-309.
[11] 刘文, 罗丹, 代小雨, 鲜于剑波, 于颖娟, 钟春林, 王东. 继发性甲状旁腺功能亢进的治疗研究进展[J]. 中华肾病研究电子杂志, 2022, 11(05): 281-284.
[12] 李丹, 谢坤, 陈倩倩, 刘昌华. 继发性甲状旁腺功能亢进症术后复发的防治[J]. 中华肾病研究电子杂志, 2021, 10(03): 166-169.
[13] 周加军, 余永武, 周涵, 刘勇, 张凌. 甲状旁腺切除对继发性甲状旁腺功能亢进患者骨密度及骨代谢的影响[J]. 中华临床医师杂志(电子版), 2023, 17(06): 706-710.
[14] 周加军, 余永武, 周涵, 张凌. 358例继发性甲状旁腺功能亢进症患者异位甲状旁腺的检出及分布情况分析[J]. 中华临床医师杂志(电子版), 2023, 17(04): 381-385.
[15] 高潮清, 刘勇, 鹿冬梅, 胡俊, 李慧, 周加军. 帕立骨化醇联合西那卡塞对尿毒症继发性甲状旁腺功能亢进患者微炎症状态、碱性磷酸酶及甲状旁腺激素水平的影响[J]. 中华临床医师杂志(电子版), 2022, 16(11): 1115-1119.
阅读次数
全文


摘要